Therapeutic Potential of New 4-hydroxy-tamoxifen-Loaded pH-gradient Liposomes in a Multiple Myeloma Experimental Model
- 303 Downloads
To determine the better liposomal formulation incorporating the active metabolite of tamoxifen, 4-hydroxy-tamoxifen (4HT) and the biological impact of 4HT-pH-gradient liposomes on response to in vivo treatment.
Several pegylated liposomes were formulated by varying the composition of lipids, increasing external pH from 7.4 to 9.0 and doubling the lipid concentration. Dipalmitoylphosphatidylcholine / cholesterol / distearoylphosphoethanolamine poly(ethylene)glycol liposomes (DL-9 liposomes) were chosen for their physico-chemical properties. Toxicity and release kinetics were assessed in breast cancer MCF-7 as well as in multiple myeloma (MM) cells. In vivo antitumor activity and bio-distribution were measured in the RPMI8226 MM model.
Compared to conventional non-pH-gradient liposomes, 4HT-DL-9 liposomes resulted in concentration of up to 1 mM 4HT, greater stability, relative toxicity and slow 4HT release. Intravenous injections of 4HT-DL-9 liposomes at 4 mg/kg/week blocked MM tumor growth. Ki67 and CD34 labeling decreased in treated tumors, concomitantly with increase of activated caspase-3 supporting a cell proliferation arrest, a decrease of tumor vasculature and the induction of tumor cell death.
This antitumor effect was assumed to be the result of a modified biodistribution of 4HT once trapped in DL-9 liposomes. Such 4HT-containing pH-gradient Stealth® nanocarriers could be helpful for MM treatment.
KEY WORDSbreast cancer hydroxy-tamoxifen multiple myeloma pH-gradient Stealth® liposomes
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(Polyethyleneglycol)-2000] (ammonium salt)
We thank Besins Iscovesco for the generous gift of 4HT, J. Bignon for FACS analyses and M. Pons and P. Ballaguer for the gift of MELN cells. This work was supported by the Ligue Nationale contre le Cancer through a fellowship offered to G.U. and financial support was provided to J-M. R from the Comités du Cher, de l’Indre et des Hauts de Seine of the Ligue Nationale contre le Cancer.
- 6.Dutertreand M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther. 2000;295:431–7.Google Scholar
- 9.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.Google Scholar
- 12.Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol. 1997;24:S1-65–70.Google Scholar
- 13.de Medina P, Payre B, Boubekeur N, Bertrand-Michel J, Terce F, Silvente-Poirot S, et al. Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism. Cell Death Differ. 2009.Google Scholar
- 16.Otsuki T, Yamada O, Kurebayashi J, Moriya T, Sakaguchi H, Kunisue H, et al. Estrogen receptors in human myeloma cells. Cancer Res. 2001;60:1434–41.Google Scholar
- 17.Gauduchon J, Gouilleux F, Maillard S, Marsaud V, Renoir JM, Sola B. The 4-hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro and in vivo through down-regulation of c-Myc, up-regulation of p27Kip1 and modulation of Bcl-2 family members. Clin Cancer Res. 2005;11:2345–54.CrossRefPubMedGoogle Scholar
- 18.Gauduchon J, Seguin A, Marsaud V, Clay D, Renoir JM, Sola B. Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases. Int J Cancer. 2008;122:2130–41.CrossRefPubMedGoogle Scholar
- 31.Renoir JM, Stella B, Ameller T, Connault E, Opolon P, Marsaud V. Improved anti-tumoral capacity of mixed and pure anti-oestrogens in breast cancer cell xenografts after their administration by entrapment in colloidal nanosystems. J Steroid Biochem Mol Biol. 2006;102:114–27.CrossRefPubMedGoogle Scholar
- 37.Daoud-Mahammed S, Couvreur P, Bouchemal K, Cheron M, Lebas G, Amiel C, et al. Cyclodextrin and Polysaccharide-Based Nanogels: Entrapment of Two Hydrophobic Molecules, Benzophenone and Tamoxifen. Biomacromolecules 2009.Google Scholar
- 44.Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, et al. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res. 2004;10:728–38.CrossRefPubMedGoogle Scholar
- 46.Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, et al. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. Eur J Pharm Biopharm. 2008;68:607–17.CrossRefPubMedGoogle Scholar
- 49.Maillard S, Ameller T, Gauduchon J, Gougelet A, Gouilleux F, Legrand P, et al. Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. J Steroid Biochem Mol Biol. 2005;94:111–21.CrossRefPubMedGoogle Scholar
- 50.Marsaud V, Gougelet A, Maillard S, Renoir JM. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol Endocrinol. 2003;17:2013–27.CrossRefPubMedGoogle Scholar
- 53.Watts CK, Brady A, Sarcevic B, deFazio A, Musgrove EA, Sutherland RL. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol. 1995;9:1804–13.CrossRefPubMedGoogle Scholar
- 60.Bhatia A, Bhushan S, Singh B, Katare OP. Studies on Tamoxifen Encapsulated in Lipid Vesicles: Effect on the Growth of Human Breast Cancer MCF-7 Cells. J Liposome Res. 2008;1-6.Google Scholar
- 66.Bouclier C, Marsaud V, Bawa O, Nicolas V, Moine L, Opolon P, et al. Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor alpha and anti-oestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts. Breast Cancer Res Treat 2009.Google Scholar